Monday, February 10, 2020

JenaValve Finds $50M Funding

Irvine-based JenaValve Technology, which develops aortic valve replacements, said last week that it has raised $50M in a financing round. The funding was led by Bain Capital Life Sciences, and also included existing investors Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. As part of the funding, Bain Capital's Andrew Hack, MD, Ph.D., has joined the company's board of directors. The company said the new funding will supports it ongoing clinical program. The company says it plans to file for U.S. Humanitarian Device Exemption (HDE) approval in the second half of 2020. More information »